Developing primary palliative care

Citation for published version:
Murray, SA, Boyd, K & Sheikh, A 2005, 'Developing primary palliative care: primary palliative care services must be better funded by both day and night' BMJ, vol 330, no. 7492, pp. 671. DOI: 10.1136/bmj.330.7492.671-a

Digital Object Identifier (DOI):
10.1136/bmj.330.7492.671-a

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
BMJ

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Developing primary palliative care

Continuity of care is paramount but needs to be tailored individually

Editor—Riley suggests that completion of a form detailing palliative care management should be mandatory for general practitioners.1 I have spent a great deal of time promoting palliative medicine in primary care, with variable success. Much depends on the individual practitioner's experience and interest, which probably accounts for the variable success of handover forms to communicate with out of hours services.

Making this a compulsory part of general practice might bring all practice to the same level. But the initial answer to the question, "Would I be surprised if my patient died in the next 12 months?" would then make the difference. Cynical practitioners would probably answer no for nearly all of their patients, for the longer you practise the less often you are surprised.

But, in truth, for many patients in general practice the answer to this question would be no: many elderly patients who live in nursing or residential homes, nearly all patients with chronic disease, including heart disease, chronic obstructive pulmonary disease, neurological disease, and so on. The workload in handling these patients over the out of hours service would be huge, more so for the out of hours service than the individual practice.

Continuity of care for patients who most need it is paramount, including all those with chronic disease. However, more sophisticated systems are needed to meet patient needs: perhaps different systems for different diseases, possibly different systems for each stage of a disease. Whatever the system, it must meet the needs of the individual patient. This entails dialogue between primary care (including out of hours), secondary care, and tertiary care to thrash out the detail.

Paul A Fox general practitioner
Stanley Health Centre, Wakefield WF3 4BH
PAFox@aol.com

Competing interests: None declared.

Primary palliative care services must be better funded by both day and night

Editor—Guthrie's response to our editorial of 6 November on developing primary palliative care is helpful in pointing out that the new out of hours organisations are now responsible for three quarters of the week's on call hours, while primary care teams working during the day are responsible for only a quarter. This of course means that general practitioners and district nurses working out of hours will often attend people dying at home.

Unfortunately such busy organisations are often extremely stretched to deal with the diverse out of hours workload, and hand over forms for identifying patients receiving palliative care who could deteriorate in the short term are in our experience rarely in place. Progress is being made by some practices which routinely notify NHS24 in Scotland or NHS Direct in England of such patients, as recommended, for instance, in the gold standards framework.2

We do not yet know what effect the new call centre triaging and accompanying out of hours arrangements will have on helping patients to die at home if they so wish. Care by call centres can be problematic and perceived as impersonal.3 This underscores the urgent need to develop plans for providing 24 hour care for dying people.

As out of hours services continue to evolve, the attempt to meet the last wishes of patients, many of whom would like to die at home if they could, must not be lost sight of. This means, as Guthrie highlights, that more community nurses and social support need to be available out of hours. Ways of targeting additional support at home for those with particularly complex needs should be explored, with community providers being encouraged to make greater use of the out of hours advice available from specialist palliative care services. Otherwise, as Levack et al suggest,4 only those with the fewest symptoms and greatest personal resources will be able to die at home.

Scott A Murray clinical reader
Scott.Murray@ed.ac.uk

Kirsty Boyd honorary senior lecturer
Aazr Sheikh professor of primary care research and development
Primary Palliative Care Research Group, Division of Community Health Sciences: General Practice Section, University of Edinburgh, Edinburgh EH8 9DX

Competing interests: None declared.

Specialist palliative care in dementia

Patients with dementia are unable to access appropriate palliative care

Editor—Hughes et al suggest that specialised units with outreach and liaison are needed for palliative care of patients with dementia.1 The United States has taken a much more holistic approach than the United Kingdom in this area. Although several papers have been published over the past few years that highlight the need for palliative care for such patients,2,3 little more than lip service is paid to this group of patients. In our experience, even if patients with dementia develop advanced cancer they are seldom admitted to specialist palliative care units, and palliative care teams are only too ready to declare such patients as having no specialist needs or not being appropriate for their service.

Evidence shows that where psychiatry and palliative care teams collaborate well, appropriate palliative care can be delivered to patients with advanced dementia wherever they may be located.4 The need for bereavement care for relatives where social death occurs many months or years before the physical death must also be included.

We advocate Hughes et al's suggestion that through outreach and liaison, palliative care for people with dementia can be delivered in the community, including in nursing and residential homes. Palliative care services need to look beyond cancer. Patients with dementia and their families have a high symptom burden and all too often are not offered or provided with the care they require.

Mari Lloyd-Williams professor
Division of Primary Care, School of Population, Community and Behavioural Sciences, University of Liverpool, Liverpool L69 3GB
mhw@liverpool.ac.uk

Sheila Payne professor
School of Nursing, University of Sheffield, Sheffield S3 7ND

Mick Dennis senior lecturer
Academic Department of Psychiatry for the Elderly, Leicester General Hospital, Leicester LE5 9QP

Competing interests: None declared.

1 Riley J. Developing primary palliative care. BMJ 2005;330:42 (1 January.)


Managing osteoarthritis of the knee

Conclusions about use of NSAIDs are misleading

Editor—The meta-analysis by Bjordal et al of randomised controlled trials assessing the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) in osteoarthritic knee pain is technically well done, but the authors’ conclusions are misleading.1 They assert that the mean change in pain, as measured on a visual analogue scale, over placebo was 10.1 mm (95% confidence interval 7.4 to 12.8) and claim a non-relevant difference, since the minimal clinically perceptible difference was 9.7 mm.

They mixed up the interpretations at group and individual levels. Indeed, 9.7 is the perceptible difference at the individual level (a change lower than 9.7 mm would not be perceived by the patient). However, the 10.1 mm estimate assessed by Bjordal et al makes sense only at the group level.

To understand this multilevel interpretation better, we performed some calculations, classifying patients as improved or not if they achieved a change greater than 10.1 mm. Thus, hypothesising that in the placebo group, the change equals 5–29 mm, 40.1% of the placebo group patients would show improvement (under the reasonable assumption of a normal distribution of change in pain on a visual analogue scale). A treatment effect of 10.1 mm leads to a mean change of 15.1 mm in the experimental group, and 60.1% of patients would therefore show improvement. The number of patients needed to treat is then estimated at 5.0, the same way, if the placebo group was 20±20 mm, 69.2% of patients would show improvement in this group and 84.3% in the experimental group, and the number needed to treat would then be 6.6. These examples show that using the minimal clinically perceptible difference to interpret changes at the group level is inadequate: a small variation at the group level does not mean no clinically relevant change in the individuals of the group.

Florenci Tubbach assistant professor of epidemiology florence.tubbach@bicp.ap-hop-paris.fr

P Ravaud professor of epidemiology INSERM U758; Groupe Hospitalier Bichat-Claude Bernard (Assistance Publique–Hôpitaux de Paris), Faculté Xavier Bichat (Université Paris 7), 46 rue Henri Fuchard, 75018 Paris, France

B Giraudie assistant professor of biostatistics INSERM CIC 029, Faculté de Médecine, 2 bis Bd Tonnelle, 37032 Tours, France

Competing interests: None declared.


Authors’ reply

Editor—Tubbach et al say that we misinterpreted data by confusing group responses and individual responses. They present hypothetical calculations that supposedly show a number needed to treat of 5-6 for non-steroidal anti-inflammatory drugs (NSAIDs) in osteoarthritis of the knee. Their calculations are based on a weighted mean difference of 10.1 mm on a visual analogue scale from our analysis. However, we showed that this group response value was inflated by patient selection bias in a subgroup of trials. When this subgroup of biased trials was excluded, the difference in our analysis in the paper, the unbiased weighted mean difference fell to 5.9 mm (3.8 to 7.9).

As a benchmark for response, Tubbach et al have selected what the inventors termed the “minimally perceptible difference” at 9.7 mm on the visual analogue scale.1 More clinically relevant benchmark in knee osteoarthritis would be the “minimal clinically important difference,” which corresponds to 19.9 mm on the scale.2 Using the unbiased weighted mean difference and the latter benchmark for treatment success, the remaining number needed to treat is in the 9-20 range.

Tubbach et al make a point of the fact that the occasional patient may experience benefit from NSAID treatment. In our view, it seems more relevant to question if patients should be put at jeopardy for adverse effects from oral NSAIDs when only a few of them are likely to notice if their NSAID is replaced by a placebo.

We stand by our conclusion that there is a lack of evidence for clinically relevant care, and other symptom control are essential components.

The assumption in the editorial by Hughes et al that pain relief is central is wrong,3 and hope for terminal care at home is inadequately considered. We think that the methodological approach to pain management needs re-evaluation.4 We also note that the problem extends beyond pain relief,6 and hope for terminal care at home is inadequately considered. 4 We also note that the problem extends beyond pain relief,6 and hope for terminal care at home is inadequately considered. 4 We also note that the problem extends beyond pain relief,6 and hope for terminal care at home is inadequately considered. 4 We also note that the problem extends beyond pain relief,6 and hope for terminal care at home is inadequately considered. 4
effects from oral NSAIDs in knee osteoarthritis pain.

Jan M Bjordal research fellow
Jan Bjordal

Anne Elisabeth Ljunggren professor
Anne Bjordal

Ate Klovning associate professor
Ate Klovning

Department of Public Health and Primary Health Care, University of Bergen, 5018 Bergen, Norway

Lars Sjørdal professor
Lars Sjørdal

Department of Laboratory Medicine, Children’s and Woman’s Health, Norwegian University of Science and Technology, 7489 Trondheim, Norway

Competing interests: None declared.


Holistic approach is important

Editor—The editorial by MacAuley on managing osteoarthritis of the knee provided a welcome emphasis on the EULAR recommended, holistic, multidisciplinary approach to the condition.

Excessive prescribing of non-steroidal anti-inflammatory drugs in primary care reflects the dependence of health professionals on “medicines based evidence” rather than evidence based medicine and the chronic underinvestment in other approaches to osteoarthritis of the knee. No reference was made to evidence of benefit of weight loss programmes linked to exercise; this is important, since increasing levels of obesity and incident knee osteoarthritis are strongly associated. Even relatively small amounts of weight loss can reduce pain and improve activity levels. At the point at which knee replacement is appropriate, severely disabled patients with a high body mass index may be denied surgery.

MacAuley comments that physiotherapy may delay decline. Community physiotherapists could have a central role in the treatment of knee osteoarthritis, using motivating clinical skills for individual or group exercise programmes, gait retraining, tapping, falls prevention, walking aids, footwear advice, and pain relief techniques including acupuncture and steroid injections.

The new cohort of NHS physiotherapy practitioners with extended scope can independently assess, treat, and improve appropriate referral to orthopaedic consultants.

A physiotherapist may be a highly appropriate lead musculoskeletal specialist in primary care, providing a functional approach to treatment to minimise disability for people with osteoarthritis of the knee and overall offering far more in a consultation than the average general practitioner.

The large community disability burden and high knee pain referral rates to orthopaedic specialists, warrant intervention at a population level and an integrated care pathway for osteoarthritis of the knee.

Primary care trusts are in an ideal position to develop expert initiatives for patients, encourage the use of community sports facilities, and promote the work of voluntary bodies such as the Arthritis Research Campaign, which provide excellent patient information and professional education resources.

Caroline A Mitchell general practitioner
Caroline A Mitchell

Woodhouse Medical Centre, Sheffield S13 7LY C.Mitchell@sheffield.ac.uk

Ade Adelaja consultant rheumatologist
Barnsley District General Hospital, Barnsley S75 2ED

Competing interests: None declared.


3 Underwood MB. Community management of knee pain in older people: is knee pain the new back pain? Rheuma
tology 2004;43:25-S.


Glucosamine-chondroitinoid should be prescribed by doctors

Editor—In his editorial on the management of osteoarthritis of the knee MacAuley recommended glucosamine-chondroitin as an off prescription preparation. Can anyone explain why it is usually recommended so, despite evidence of efficacy that is as good or better than most non-steroidal anti-inflammatory drugs (NSAIDs), which cause a huge burden of morbidity and mortality?

Yet NSAIDs, and cleverly marketed variations of the theme, continue to be licensed and adopted for NHS prescription for osteoarthritis, and I presume will continue to do so despite the debacle surrounding the cyclo
oxynase 2 inhibitors. Remember also benecaprofen 25 years ago.

Most patients with osteoarthritis will qualify for free prescriptions and are in the age group with least income flexibility. Most do not need surgery but are still suffering. I understand that glucosamine is prescribable, but rheumatologists and general practitioners seem to advise patients to buy their own—why? I fear that the background to this is the huge threat to NSAID sales that is posed by any form of help that patients with osteoarthritis may receive from other sources. But why spend on many expensive NSAIDs, with no convincing overall benefit to patients over cheaper alternatives (and sometimes major harms), and not on glucosamine-chondroitin?

Roger Chalmers full time NHS locum general practitioner
Barry St Edmunds, Suffolk IP31 3TE rachalmers@onetel.com

Competing interests: RC is concerned about the damaging effect of drug companies’ influence on NHS and doctors’ decisions in the interest of patients.


Opioids help manage pain in osteoarthritis

Editor—MacAuley raises an important point about the poor long term management of pain in osteoarthritis of the knee. A recent survey carried out by Osteoarthritis Care to assess the impact of osteoarthritis on patients showed that 81% of the sample said they experience constant pain and that when their osteoarthritis is bad, 69% have difficulty carrying out even the simplest of daily household tasks. Exercise is undoubtedly of benefit to patients with mild to moderate osteoarthritis, so the priority of healthcare professionals should be the symptomatic relief of chronic pain. Along with paracetamol and non-steroidal anti-inflammatory drugs there is further ammunition for pain relief. Opioids can and should be considered in these patients. As stated by the Pain Society, the primary effect of the appropriate use of opioids in chronic pain is analgesia that leads to improved function, sleep, and reduced distress. Their use may also result in reduced use of other analgesics.

With improved education of healthcare professionals and the patient, opioid treatment can be initiated and managed in primary care through developing an individualised treatment plan in discussion with the patient. Doctors in general practice should therefore recognise that appropriate prescribing of opioids can offer a substantial improvement in a patient’s quality of life.

Martin Johnson general practitioner
Ashville Medical Centre, Barnsley S70 3RJ mjohnson@profial.com

Competing interests: MJ has carried out consultancy work with Napp Pharmaceuticals, Pfizer, Janssen-Cilag.

United Kingdom back pain exercise and manipulation (UK BEAM) trial

Touch may have had non-specific effect, among other things

Editor—I have three brief comments on the United Kingdom back pain exercise and manipulation (UK BEAM) trial.

Firstly, the data are compatible with a non-specific effect caused by touch. If this “dev- il’s advocate” view is correct, the effects have little to do with spinal manipulation itself.

Secondly, which of the three professional groups (chiropractors, osteopaths, physiotherapists) generated the largest effect size is relevant. This might significantly influence the referral pattern. A post-hoc analysis might answer this question.

Lastly, the study monitored only serious adverse effects. Data show that minor

Letters

BMJ VOLUME 330 19 MARCH 2005 bmj.com

673
adverse effects occur in about 50% of patients after spinal manipulation. Such adverse effects might then also influence general practitioners’ referrals.

Edward Ernst
director
Complementary Medicine, Peninsula Medical School, Exeter EX2 4NT
Edward.Ernest@pmsa.ac.uk

Competing interests: None declared.

1 UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care. BMJ 2004;329:1577-81. (11 December.)

2 Stevinson C, Ernst E. Risks associated with spinal manipulation and best care were of equal benefit. It seems that adverse effects occur after 50% of spinal manipulations.


toril Hydevåg research fellow
Department of Biological and Medical Psychology, University of Bergen, Jonas Lieveid 91, N-5009 Bergen, Norway

Competing interests: None declared.

1 UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care. BMJ 2004;329:1577-81. (11 December.)

2 UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. BMJ 2004;329:1581-5. (11 December.)


Manipulation alone costs more than other options so why is it recommended?

Editor—It is not clear why the UK Beam Trial Team recommends manipulation alone for back pain because it costs more per quality adjusted life year (QALY) than exercise and manipulation combined and even slightly more than exercise alone. The average effect of exercise and manipulation combined is also larger than the other two in absolute terms.

Timothy R Church associate professor
University of Minnesota, Minneapolis, MN 55455, USA
trc@ccimusmed.edu

Competing interests: None declared.

1 UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. BMJ 2004;329:1581-5. (11 December.)

Authors’ reply

Editor—Ernst is correct that the beneficial effects UK BEAM found for manipulation could be a non-specific effect. This was a pragmatic study testing a package of manipulative treatment, not an explanatory study seeking to assess the effect of manipulation itself.

All the manipulation practitioners used a common treatment package agreed by the three professional groups. Any comparisions between the professions would be underpowered and, because patients were allocated to therapists nearest their home, non-randomised. Such a comparison was specifically precluded when the professions agreed to the treatment package.

Ernst’s data do not support the assertion that adverse effects occur after 50% of spinal manipulations. Such effects are usually minor and short lived. Set against the positive effect of being able to do one more daily activity one year later we would not expect this to influence general practitioners’ referrals decisions.

Tillett is concerned about our follow up rate. For a large nationwide trial of this nature it was, if anything, better than might be expected. Since the characteristics of those lost to follow up were consistent across all randomised groups, and the largest difference in follow up rates between treatment and control groups was only 4.1%, little risk of bias exists. Our sensitivity analysis, using the last observation carried forward, does not change our findings.

Tveito and Ernsen argue that we should recommend adding exercise to “best care” even though exercise did not produce a statistically significant benefit at one year and its overall cost is greater than either manipulation or best care. Our data do not support the premise that manipulation and exercise are equally effective. The evidence benefits of the BEAM interventions for individual patients are small. However, at a population level, our manipulation or combined packages produce an overall benefit at modest cost, as other healthcare use fell during the following year.

Church is unclear on our health economic conclusions. We are not recommending manipulation as the only treatment option. Instead we are saying that the UK BEAM manipulation package is the best strategy should the decision maker be willing to pay £8700 or more for each additional quality adjusted life year (QALY). If a decision maker is willing to pay > £3800 and < £8700 per additional QALY, combined treatment is the best strategy. When the decision maker is willing to pay < £3800 per QALY general practitioner care is the best strategy.

Martin Underwood professor of general practice
Centre for General Practice and Primary Care, Institute of Community Health Sciences, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry, Queen Mary University of London, London E1 2NS
underwood@jsrml.ac.uk

On behalf of the UK BEAM Trial Team

Competing interests: MU has received a salary from the MRC and fees for speaking from Menarini Pharmaceuticals, the manufacturers of desloratadine and ketoprofen, and Pfizer, the manufacturers of celecoxib and valdecoxib.

